Background: Osseous-associated cervical spondylomyelopathy (OA-CSM) is a common condition of the cervical vertebral column that affects giant dog breeds. Micro-RNAs (miRNAs) are small RNAs that regulate gene expression, and recent data suggest that circulating miRNAs present in biological fluids may serve as potential biomarkers for disease. The miRNA profiles of cerebrospinal fluid (CSF) from healthy dogs and dogs clinically affected by OA-CSM have not been described. Objective: To characterize the expression levels of miRNAs present in the CSF of normal Great Danes and identify differentially expressed miRNAs in the CSF of Great Danes clinically affected with OA-CSM. Animals: Client-owned dogs: 12 control, 12 OA-CSM affected. Methods: Cerebrospinal fluid samples were collected prospectively. MicroRNA expression was evaluated using the NanoString nCounter platform and quantitative real-time PCR.
| INTRODUCTION
MicroRNAs (miRNAs) are highly conserved, small (18-25 nucleotides) RNAs that play important roles in regulating gene expression in animals.
MicroRNAs repress gene expression by binding to complementary
sequences present in the 3 0 untranslated region of target mRNAs, which promotes translational repression, transcript degradation, or both. 1, 2 Distinct tissue-specific miRNA expression profiles and circulating miRNAs in biological fluids such as plasma, serum, urine, and cerebrospinal fluid (CSF) have been identified in a number of species including dogs. 1, 3 Circulating miRNAs found in these fluids are thought to contribute to disease pathogenesis. For example, the expression of miR-7-5p, miR-331-5p, and miR-145-5p in the CSF is associated with Parkinson's disease in humans, suggesting that circulating (or secreted) miRNAs may play a role in cellular cross talk, disease pathogenesis, or both. 4 Consequently, circulating (or secreted) miRNAs present in bodily fluids may serve as biomarkers for the diagnosis and monitoring of disease. 5, 6 To date, few studies have characterized miRNA expression in canine CSF. A study conducted in dogs with meningoencephalomyelitis found that several miRNAs implicated in the pathogenesis of the disease counterpart in humans, miR-21 and miR-181c, are detectable in the CSF and serum of affected dogs. 7 A recent study evaluated the expression of 14 miRNAs with known roles in central nervous system (CNS) diseases of humans, in the CSF of 20 dogs with various neurological conditions. Seven of these miRNAs were amplified from canine CSF samples, and increased miR-10b-5p expression was identified in CSF samples from dogs with neoplastic disease. 8 Canine cervical spondylomyelopathy (CSM) is a common condition in large and giant breed dogs causing narrowing of the vertebral canal leading to progressive cervical spinal cord compression. Two forms of the disease exist: osseous-and disc-associated CSM (OA-CSM and DA-CSM). The OA-CSM form is found predominantly in young adult Great Danes and other giant breeds, whereas the disc-associated form is seen mainly in middle-aged Dobermans. 9 Few treatment advances have been made in recent years. A number of surgical and medical management techniques have been described for DA-CSM, [10] [11] [12] [13] but surgical treatment has comparable long-term survival to medical management and no important advances in treatment for dogs with OA-CSM have been made in the last decade. 9, 14, 15 Studies have investigated molecular factors thought to play a role in the pathogenesis of OA-CSM in dogs, identifying dysregulation of inflammatory cytokines interleukin-6, monocyte chemoattractant protein-1, and chemokine ligand 2 and alterations in vitamin-D binding protein, angiotensinogen, and complement C3 proteins. 16, 17 A better understanding of the pathophysiology and mechanisms underlying OA-CSM will be critical to identify potential targets for treatment and develop biomarkers to monitor response to treatment and to identify treatment responders.
No prior studies have investigated the potential role of miRNAs in the pathogenesis of OA-CSM. We sought to characterize the expression levels of miRNAs present in the CSF of clinically normal Great Danes and identify differentially expressed miRNAs in the CSF of Great Danes clinically affected with OA-CSM.
| MATERIALS AND METHODS

| Cerebrospinal fluid collection and storage
Cerebrospinal fluid samples were prospectively collected as part of a different study, 16, 17 and remaining CSF was banked for prospective evaluation of the miRNA expression profile of Great Danes. The study was conducted in accordance with the guidelines and with approval of the institution's Clinical Research Advisory Committee and the Institutional Animal Care and Use Committee. Samples were collected from 12 clinically normal and 12 CSM-affected Great Danes. Dogs were defined as clinically normal based on findings of a normal neurological examination, no history of neurological disease, and normal cervical spine magnetic resonance imaging (MRI). The OA-CSM affected dogs were identified and included in the study if they exhibited clinical signs and neurological examination findings consistent with a diagnosis of cervical myelopathy. All dogs included in the study underwent standardized gait grading, 16 cerebellomedullary cistern CSF collection, and MRI of the cervical vertebral column. The OA-CSM was confirmed on MRI by 2 investigators (P.M.V. and D.V.). Spinal cord compression was graded as mild, moderate, or severe as previously described. 16 The sites of spinal cord compression and the presence or absence of spinal cord signal changes were determined based on sagittal and transverse T2-weighted images of all intervertebral disc spaces of the cervical vertebral column. The site with the most severe spinal cord compression was used for statistical analysis. After MRI, cerebellomedullary cistern CSF samples (1-2 mL) were collected using sterile technique under general anesthesia into fluid collection tubes without additives. The CSF from each dog was immediately centrifuged at 3000 rpm for 8 minutes to remove cellular materials. An aliquot of each CSF sample was evaluated by a board-certified veterinary clinical pathologist to determine total nucleated cell count, red blood cell (RBC) count, protein concentration, and cytology findings. This technique was described previously as part of a different study. 16 The remaining CSF aliquots were stored at −80 C for subsequent miRNA analysis. Thorold, Ontario, Canada). The samples were assessed for any contaminants that could affect the assay using Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, Massachusetts).
| RNA isolation
| NanoString nCounter assay
Prior studies have characterized miRNA expression in normal canine tissues using the NanoString nCounter Human v3 miRNA Expression Assay (NanoString, Seattle, Waltham), validating this assay as a platform to profile the expression of miRNAs in samples from dogs. 3, 18 This assay allows detecting and measuring expression levels of up to 800 human miRNAs; the mature sequences of 168 which are 100% conserved between human and dog (Sanger miRbase V16). For miRNA profiling of canine CSF samples, 3 μL of RNA were annealed with multiplexed DNA tags (miR-tag) and target-specific bridge probes. Mature miRNAs were bound to specific miR-tags using a ligase enzyme, and all tags in excess then were removed using the enzyme clean-up step. The tagged miRNA product then was diluted (ratio 1:5), and 5 μL were combined with 20 μL of reported probes in hybridization buffer and 5 μL of capture probes. 
| NanoString data analysis
Abundances of miRNA were quantified using the NanoString nCounter gene expression software. 19 Boxplot analysis did not detect obvious batch effect or poor sample integrity. Therefore, all data were used for analysis. Raw data were normalized using internal positive control probes included in each assay and then a filtering step was applied. Internal negative control probes were used to determine a background threshold (2 standard deviations above the mean negative control probe count value), and if >90% of the samples had miRNA expression lower than the background threshold cutoff value, those miRNAs were filtered out. hsa-miR-494-3p, hsa-miR-612, and hsa-miR-302d-3p were determined using miRNA sequence-specific Taqman probes according to manufacturer's instructions (TaqMan Advanced miRNA assays:   MI0000744, MI0003134, MI0003625, MI0000774; see Table 1 for mature miRNA sequences). Sequences for the remaining miRNAs (hsa-miR-765, hsa-miR-4531, hsa-miR-4455, and hsa-miR-6721-5p)
| Quantitative real-time PCR
were not identified in the canine genome and therefore we were unable to use commercially available Taqman primer-probe sets to evaluate expression levels. Briefly, miRNA-specific cDNA was generated from 5 μL of total RNA using the TaqMan Advanced miRNA cDNA Synthesis Kit (Thermofisher), followed by real-time PCR with Taqman probes according to the manufacturer's protocol. All reactions were run in triplicate wells and included non-template controls.
All samples were normalized to synthetic non-mammalian oligo spike-in cel-miR-254 (TaqMan Advanced miRNA assay: MIMAT0000310, mature sequence: UGCAAAUCUUUCGCGACUGUAGG). intramedullary signal intensity in the OA-CSM affected dogs. The severity of clinical signs was graded based on the gait analysis as previously described. 16 Dogs with moderate and severe OA-CSM were grouped and compared to the mildly affected dogs. For the comparison of lesion localization, the number of dogs with the most compressive lesion located at C6-C7 was compared to the other localizations. Real-time PCR miRNA data were first normalized to internal control (miR-254) and the delta-delta Ct method 20 was used to compare miRNA expression by using the Student's t test. P ≤ .05 were considered significant.
| Statistical analysis
| RESULTS
The detailed characteristics of the OA-CSM affected and clinically normal Great Danes are summarized in Table 1 . Gait scores were as follows: 6 were categorized as mild (gait score 1 or 2), 3 were categorized as moderate (gait score 3 or 4), and 3 were categorized as severe (gait Table 1 for median and ranges of red and white blood cell counts and protein concentrations.
| Global miRNA expression in the CSF of clinically normal dogs
To begin to characterize the expression levels of miRNA present in the CSF of clinically normal Great Danes, global miRNA expression profiling was performed on CSF samples from 12 clinically normal dogs using the NanoString nCounter platform. Using this method, we detected 153 miRNAs in control dog CSF and the 15 miRNAs that showed the highest levels of expression in CSF are represented in 
| Differential miRNA expression in the CSF of Great Danes affected by OA-CSM
We identified 8 miRNAs that showed significant differential expression in the CSF of dogs affected by OA-CSM compared to that of clinically normal dogs ( Table 2 ). Unsupervised hierarchical cluster analysis readily separated patient CSF samples based on whether they were from clinically normal or OA-CSM-affected dogs, providing support for the notion that a unique miRNAs expression signature is associated with dogs affected by OA-CSM ( Figure 2 
| Independent validation of the NanoString nCounter assay results by qRT-PCR
| Association of miRNAs with imaging characteristics and severity of clinical findings
We evaluated differences in miRNA expression in canine OA-CSM patients with differential lesion localization or increased intramedullary signal intensity on MRI, but no significant differences in miRNA expression were observed, suggesting that the CSF miRNA signature in dogs with OA-CSM does not reflect differences in lesion location or imaging findings. We further investigated whether dogs with OA-CSM exhibiting more severe clinical signs had differences in CSF miRNA expression levels. Interestingly, we found that hsa-miR-1246 (P = .004) and hsa-miR-1322 (P = .02) were significantly overexpressed in OA-CSM dogs with more severe gait grade compared to dogs with a mild or moderate We evaluated the miRNA expression pattern in CSF samples from normal and affected Great Danes. Data generated from studies in humans suggest that interrogating the expression of miRNAs in CSF samples may be more accurate in identifying miRNAs that play a causal role in diseases of the CNS as compared to serum or plasma. 5, 6, 21 It is known that brain-derived miRNA are present in a higher proportion in CSF samples compared to serum samples, and the miRNA profile in human CSF has been found to be almost identical to that of human brain tissue. 6, 21 Cerebrospinal fluid is in direct contact with the brain and spinal cord, and provides a relatively cell-free environment compared to blood. 6 All clinically normal dogs had normal CSF analysis apart from 1 sample with marked blood contamination, which made these sam- , but it is possible that this dog may have been asymptomatic or had early onset or dynamic OA-CSM in the absence of detectable imaging changes. 24 Asymptomatic OA-CSM is recognized in people, 25 horses, 26 and dogs, 22, 27 and has been described in Doberman
Pinschers with DA-CSM 27 and reported in Great Danes with OA-CSM. 22 We subsequently evaluated the expression of 2 OA-CSM-associated miRNAs, miR-494, and miR-612, using qRT-PCR assays. Although the expression levels of these miRNA were not found to be statistically significant when evaluated by qRT-PCR, this finding may be due, in part, to differences in assay sensitivity, false positives with qRT-PCR associated with a 2-step amplification process, and miRNA primer probe efficiency.
These results warrant further investigation in a larger cohort of patients.
The role of these dysregulated miRNAs in CSF has not yet been elucidated, but in experimental models of intervertebral disc degeneration in humans, increased expression of miR-494 promotes apoptosis in nucleus pulposus cells. 28 A challenging aspect of the clinical management of OA-CSM in dogs is predicting which subset of patients eventually will show clinical deterioration and which will remain stable. One prognostic indicator in humans is the signal intensity of the spinal cord on MRI, 32, 33 However, the degree of spinal cord compression does not always correlate with the severity of clinical signs. 27 In our study, upregulation of miR-1246 and miR-1322 was found to be associated with severity of clinical signs in OA-CSM-affected dogs. High expression of miR-1246 has been documented in mesenchymal cells, and data suggest that this miRNA may play a role in the regulation of pro-inflammatory factors such as interleukin-6, chemokine ligand 2 and chemokine ligand 5 in mesenchymal cells. 34 Studies have demonstrated that miR-1322 expression is increased in humans with intervertebral disc degeneration compared to those with spinal cord injury, but little is known regarding the function of miR-1322 in this disease process. 35 Such information may be important in determining why some dogs with OA-CSM do worse than others. MiR-1246 appears to upregulate certain inflammatory mediators in mesenchymal cells that have been associated with OA-CSM, 16 but no information is available regarding its role in other cells such as osteoblasts.
A limitation of our study is that paired serum or plasma samples were not available for this population of dogs. Evaluation of the circulating miRNA profile in these dogs would be of interest to determine whether CSF-associated miRNAs are detectable in blood and if such a finding could reflect a breakdown in the blood brain barrier. Because Further studies are necessary to evaluate if these dysregulated miRNAs reflect miRNA patterns in a larger cohort of patients and in diseased tissue of Great Danes with OA-CSM. The limited number of samples analyzed in our study precludes the ability to draw major clinical associations.
| CONCLUSION
Ours is the first study to characterize the miRNA profile in the CSF of clinically normal and OA-CSM-affected Great Danes. We have identified a unique CSF miRNA expression profile, based on the NanoString nCounter assay results, that is associated with OA-CSM and determined that miRNAs are differentially expressed in the CSF of Great Danes clinically affected by OA-CSM compared to clinically normal Great Danes. These findings support the hypothesis that CSF miRNA expression is altered in dogs with OA-CSM. The specific role of these altered miRNAs remains to be determined.
